More than half a million new cases of head and neck squamous cell carcinoma (HNSCC) will occur in 2011, including 50,000 cases in the United States, making it the sixth most common cancer in the worid. These cancers are frequentiy lethal, with a five-year survival of only ~50%. Our group found that HNSCC is characterized by tumor suppressor gene predominance. This distinction is critical because the new generation of moleculariy-targeted therapies is directed toward activated oncogenes but such drugs cannot directly target mutated tumor suppressor genes because they are already inactivated. Given the lack of targeted therapies that are available for HNSCC, eariy detection, monitoring, and surveillance will be critical to decrease the morbidity and mortality associated with HNSCC. The ultimate goal ofthis proposal is to develop clinically useful biomarkers that can be used for early detection, monitoring, surveillance, and prognosis. To achieve this goal, we propose a detailed genetic analysis of HNSCC (AIM #1). These genetic changes will be used to develop and validate circulating tumor DNA based biomarker assay in HNSCC (Aim #2). The biomarkers will be con-elated with clinical findings and outcomes in a prospective study (Aim #3). The above studies will identify genetic changes in HNSCC and allow the development of clinically useful biomarkers.

Public Health Relevance

HNSCC is driven by mutations in tumor suppressor genes, precluding the use of targeted therapies. Eariy detection, monitoring disease burden during treatment to confirm efficacy of surgery, radiotherapy and/or chemotherapy, and surveillance for eariy detection of persistent or recurrent disease are the optimal approaches for reducing morisidity and mortality from this disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Specialized Center (P50)
Project #
5P50DE019032-13
Application #
8703522
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
13
Fiscal Year
2014
Total Cost
$353,317
Indirect Cost
$128,460
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Thompson, Elizabeth D; Stelow, Edward B; Mills, Stacey E et al. (2016) Large Cell Neuroendocrine Carcinoma of the Head and Neck: A Clinicopathologic Series of 10 Cases With an Emphasis on HPV Status. Am J Surg Pathol 40:471-8
Guo, Theresa; Rettig, Eleni; Fakhry, Carole (2016) Understanding the impact of survival and human papillomavirus tumor status on timing of recurrence in oropharyngeal squamous cell carcinoma. Oral Oncol 52:97-103
Stansfield, John C; Rusay, Matthew; Shan, Roger et al. (2016) Toward Signaling-Driven Biomarkers Immune to Normal Tissue Contamination. Cancer Inform 15:15-21
Kang, Hyunseok; Tan, Marietta; Bishop, Justin A et al. (2016) Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma. Clin Cancer Res :
Motz, Kevin; Qualliotine, Jesse R; Rettig, Eleni et al. (2016) Changes in Unknown Primary Squamous Cell Carcinoma of the Head and Neck at Initial Presentation in the Era of Human Papillomavirus. JAMA Otolaryngol Head Neck Surg 142:223-8
Guo, Theresa; Eisele, David W; Fakhry, Carole (2016) The potential impact of prophylactic human papillomavirus vaccination on oropharyngeal cancer. Cancer 122:2313-23
Walline, Heather M; Carey, Thomas E; Goudsmit, Christine M et al. (2016) High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res :
Rettig, Eleni M; Talbot Jr, C Conover; Sausen, Mark et al. (2016) Whole-Genome Sequencing of Salivary Gland Adenoid Cystic Carcinoma. Cancer Prev Res (Phila) 9:265-74
Sun, Yun-Yan; Peng, Shiwen; Han, Liping et al. (2016) Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res 22:657-69
Fakhry, Carole; Qualliotine, Jesse R; Zhang, Zhe et al. (2016) Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila) 9:135-41

Showing the most recent 10 out of 109 publications